Michael John Tomsicek's Net Worth
$8.2 Million
Who is Michael John Tomsicek?
Michael John Tomsicek has an estimated net worth of $8.2 Million. This is based on reported shares across multiple companies, which include ABIOMED INC, Milestone Pharmaceuticals Inc., CRISPR Therapeutics AG, CUBIST PHARMACEUTICALS INC, and Acrivon Therapeutics, Inc..
SEC CIK
Michael John Tomsicek's CIK is 0001570392
Past Insider Trading and Trends
2014 was Michael John Tomsicek's most active year for acquiring shares with 12 total transactions. Michael John Tomsicek's most active month to acquire stocks was the month of February. 2015 was Michael John Tomsicek's most active year for disposing of shares, totalling 16 transactions. Michael John Tomsicek's most active month to dispose stocks was the month of December. 2014 saw Michael John Tomsicek paying a total of $485,537.21 for 65,870 shares, this is the most they've acquired in one year. In 2021 Michael John Tomsicek cashed out on 51,352 shares for a total of $3,630,777.16, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
ABIOMED INC No price found
Vice President, CFO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -12.66% | -3.92K |
$145.07 | -$569,399.75 | 27.08K |
Jul 15
| |||
Form 4
| -4.29% | -1.57K |
$134.74 | -$211,137.58 | 34.93K |
May 24
| |||
Form 4
| +36.19% | 9.7K |
—
|
—
| 36.5K |
May 15
| |||
Form 4
| +7.20% | 1.8K |
—
|
—
| 26.8K |
Jul 15 - May 24
| |||
Form 4
|
∞
| 25K |
—
|
—
| 25K |
Jul 15
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Milestone Pharmaceuticals Inc. (MIST) Snapshot price: $1.525
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 7
| |||
Form 4
|
∞
| 15K |
$5.32 | $79,800.00 | 15K |
Oct 19
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 5
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
CRISPR Therapeutics AG (CRSP) Snapshot price: $66.91
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
$78.14 | -$3,019,176.36 | 1.89K |
Scheduled
|
Mar 11 - Aug 6
| ||
Form 4
| +361.22% | 1.48K |
$124.15 | -$167,850.80 | 1.89K |
Mar 10 - Mar 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 5
| |||
Form 4
|
—
|
0
|
$55.01 | -$894,068.00 | 410 |
Scheduled
|
Sep 1
| ||
Form 4
|
—
|
0
|
$52.25 | -$827,918.53 | 410 |
Scheduled
|
Nov 13 - Aug 3
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 13
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
CUBIST PHARMACEUTICALS INC No price found
SVP & Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -15.96K |
$102.00 | -$1,628,328.00 |
0
|
Jan 21
| |||
Form 4
| +140.79% | 8.63K |
$62.11 | -$674,770.57 | 14.77K |
Dec 29
| |||
Form 4
| +5.55% | 63 |
$66.34 | $4,179.42 | 1.2K |
Sep 30
| |||
Form 4
| +15.89% | 841 |
$63.68 | -$26,043.24 | 6.13K |
Aug 15 - Aug 18
| |||
Form 4
| +7.78% | 82 |
$69.82 | $5,725.24 | 1.14K |
Jun 30
| |||
Form 4
| +23.33% | 1K |
$69.00 | -$34,431.00 | 5.29K |
May 13 - May 14
| |||
Form 4
| +27.30% | 920 |
$64.00 | -$28,224.00 | 4.29K |
Apr 15 - Apr 16
| |||
Form 4
| +7.88% | 77 |
$73.15 | $5,632.55 | 1.05K |
Mar 31
| |||
Form 4
| +43.96% | 1.03K |
$75.00 | -$41,625.00 | 3.37K |
Feb 14 - Feb 18
| |||
Form 4
| +8.19% | 74 |
$63.55 | $4,702.70 | 977 |
Sep 30
| |||
Form 4
| -14.59% | -400.00 |
$64.08 | -$25,632.00 | 2.34K |
Sep 3
| |||
Form 4
| +83.84% | 1.25K |
—
|
—
| 2.74K |
Aug 15
| |||
Form 4
| +20.18% | 402 |
$42.49 | $16,070.63 | 2.39K |
Jun 28
| |||
Form 4
| +529.84% | 1.01K |
$49.18 | -$23,999.40 | 1.2K |
May 13 - May 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 15
| |||
Form 4
| +15.86% | 108 |
$46.82 | $5,056.56 | 789 |
Mar 28
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Acrivon Therapeutics, Inc. (ACRV) Snapshot price: $3.68
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||